Tag Archives: FDA approved ADC

03Aug/18

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

August 3, 2018Antibody-drug Conjugates Research, Newsantibody drug conjugates, breast cancer, FDA approved ADCbioadc

On July 18, Immunopharmas, a leading biopharmaceutical company in the field of antibody-drug conjugates, announced that the Biologics License Application (BLA) of its sacituzumab govitecan for the treatment of metastatic triple-negative breastRead More…

05Jul/18

Nat Commun: Novel Tumor Targeting Antibody Drugs Conjugation Effectively Treat Colon and Ovarian Cancer

July 5, 2018Antibody-drug Conjugates Research, Newsantibody drug conjugates, cancer treatment, drug release, FDA approved ADCbioadc

Tagworks Pharmaceuticals in the University of Nijmegen Medical Center has developed a new technology that targets tumor to deliver chemotherapy drugs in extreme cases. By controlling the “click release” of a chemotherapeuticRead More…

11May/18

Antibody–drug Conjugates: Historical Developments

May 11, 2018Antibody-drug Conjugates Researchadc research, antibody drug conjugates, FDA approved ADC, mmae, PtLnXbioadc

A Simple Concept of Antibody-drug Conjugates (ADCs) Developing new anticancer chemotherapeutic drugs showing superior antitumor efficacy with reduced toxicity is continuing to be a challenging endeavor. Antibody-drug conjugates (ADCs) are an emergingRead More…